FindTrial
Sign In

Preemptive therapy guided by BCR-ABL transcript levels after HLA-identical sibling donor transplantation improves HSCT outcomes for patients with chronic myeloid leukemia

Preemptive therapy guided by BCR-ABL transcript levels after HLA-identical sibling donor transplantation improves HSCT outcomes for patients with chronic myeloid leukemia

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-PRNRC-09000307
Enrollment
Unknown
Registered
2009-01-12
Start date
2004-11-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic myeloid leukemia

Interventions

Low-risk group:Protocol 1: Immunosuppressant withdrawal. Protocol 2: Imatinib therapy. Protocol 3: Modified donor lymphocyte infusion
High-risk group:Protocol 1: Immunosuppressant withdrawal. Protocol 2: Imatinib therapy. Protocol 3: Modified donor lymphocyte infusion.

Sponsors

Peking University People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
12 Years to 51 Years

Inclusion criteria

Inclusion criteria: Patients with chronic myeloid leukemia who are candidates of allogeneic hematopoiectic stem cell transplantation, consent forms were signed

Exclusion criteria

Exclusion criteria: Patients with chronic myeloid leukemia who have no suitable donors or whose economic situation is poor

Design outcomes

Secondary

MeasureTime frame
Overall survival and leukemia-free survival,relapse, and treatment-related mortality;—

Primary

MeasureTime frame
graft-versus-host disease;—

Countries

China

Contacts

Public ContactHuang Xiaojun
xjhrm@medmail.com.cn+86 010 88324984

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026